Serum microRNAs as biomarkers for the therapeutic response to trastuzumab/pertuzumab/taxane therapy in HER2-positive metastatic breast cancer

Serum microRNAs profiles of HER2 positive advanced breast cancer patients and their treatment response after the trastuzumab/pertuzumab/taxane therapy Association between serum microRNA profiles and response to trastuzumab/pertuzumab/taxane therapy of 30 advanced breast cancer patients.